Will Wegovy Tablets Work If You've Previously Failed On Wegovy Injections?

I want to start by saying something that does not get said enough in articles like this: if the injections did not work for you, that is not a failure on your part. It is a clinical signal, and it deserves a proper clinical response, not a shrug and a suggestion to try harder.

This question lands in consultations regularly. People come having spent months on Wegovy injections, frustrated, confused, and sometimes embarrassed, wanting to know whether a tablet version would change anything. The honest answer is: it depends entirely on why the injections did not work for you. Let me explain what I mean.

The Honest Answer First: It Is Not a Simple Yes or No

When someone says Wegovy injections did not work, the first thing to understand is what "did not work" actually means for them specifically. Did the side effects make it impossible to continue? Did they complete the full course but not lose the weight they hoped for? Did they struggle with the injections themselves? Or did they see results initially but then plateau?

Each of those is a genuinely different clinical situation, and each points to a different conclusion about whether switching to a tablet is worth pursuing.

What Wegovy Tablets Actually Are (And Why They Are Different From What You May Expect)

Wegovy tablets contain the same active ingredient as Wegovy injections: semaglutide. Semaglutide belongs to a class of medicine called GLP-1 receptor agonists. It essentially mimics a hormone called glucagon-like peptide-1, which your body naturally produces after eating. It helps regulate appetite, slows down how quickly your stomach empties, and supports blood glucose control. NICE guidelines support its use for weight management in adults with a BMI of 35 or above, or 30 and above with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity.

But oral and injectable semaglutide are not the same thing in terms of how the body processes them, even though the active ingredient is identical.

The oral version uses a clever absorption technology called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to get the semaglutide molecule through the acidic environment of the stomach and into the bloodstream. The Wegovy tablet, approved by the MHRA in June 2026 specifically for weight management, uses the same SNAC technology but at higher doses, and it is a separate licensed product to Rybelsus. They are not interchangeable.

What also matters clinically is bioavailability. Oral semaglutide absorbs less efficiently than the injectable form. Your body takes up a smaller proportion of the active drug from a tablet than from a subcutaneous injection. This is not a flaw in the product; it is a pharmacological reality that the dosing has been designed around. For a broader comparison of oral semaglutide products, our overview of Rybelsus vs Ozempic provides useful background reading.

Why Some People Do Not Respond Well to Wegovy Injections

Side Effects Were Intolerable

This is one of the most common reasons. Nausea, vomiting, diarrhoea, and gastrointestinal discomfort are well-documented with injectable semaglutide, particularly during the dose escalation phase. For many patients, these effects settle down after the first few weeks. For others, they do not, and continuing simply becomes untenable. If this was your experience, it is worth knowing that the gastrointestinal tolerability profile can differ between the injection and the tablet. Some patients do report a different pattern of side effects with oral semaglutide. This is a legitimate clinical reason to have a conversation with a prescriber about trying the tablet form.

Insufficient Weight Loss Despite Completing the Course

This one is harder. If you completed a full treatment programme at the target dose and the weight loss was genuinely insufficient, switching to an oral form at currently licensed doses is not likely to produce a dramatically different outcome. The tablet does not deliver more semaglutide to your bloodstream than the injection; in fact, it delivers less efficiently. What may be worth exploring in this situation is whether tirzepatide (Mounjaro) might be a more appropriate option. It works differently, targeting both GLP-1 and GIP receptors, and for some patients that dual mechanism produces meaningfully better results.

Injection Anxiety or Administration Difficulties

Self-injecting weekly is not trivial, and for some patients the psychological barrier is simply too significant to overcome. If this was the primary reason you stopped, then an oral tablet removes that barrier entirely, and the clinical case for trying it is much more straightforward, provided you meet the eligibility criteria.

Plateau or Weight Regain After Initial Success

If Wegovy worked well initially and then stopped, or if you regained weight after finishing the course, that is a separate clinical conversation. The cause is usually physiological adaptation, changes in lifestyle factors, or the need for a longer-term treatment strategy. This needs proper prescriber input rather than a formulation switch on its own.

What the Clinical Evidence Says About Oral Versus Injectable Semaglutide

The evidence base for injectable semaglutide 2.4mg (Wegovy) is substantial and well-established. The STEP clinical trial programme, published in the New England Journal of Medicine, demonstrated average weight reductions of approximately 15% of body weight over 68 weeks in adults without type 2 diabetes. This is the evidence that underpins NICE Technology Appraisal TA875.

The OASIS 1 trial, published in The Lancet, investigated oral semaglutide at 50mg per day and participants achieved mean weight reductions of around 15%, broadly comparable to the injectable form. The licensed Wegovy tablet uses a lower maximum dose of 25mg daily, reflecting the regulatory and clinical assessment of the appropriate therapeutic range for this formulation.

Following MHRA approval on 11 June 2026, the Wegovy tablet is now licensed in the UK for weight management, making it the first GLP-1 receptor agonist tablet approved for this purpose in the UK. The tablet uses a graduated dosing schedule, starting at 1.5mg daily and stepping up over several months to 25mg. Importantly, if you have previously been treated with the 2.4mg weekly injection, you may be able to transition directly to the 25mg daily tablet without starting from the bottom of the dose schedule. That is a clinically meaningful point worth raising with your prescriber.

The Role of a Prescriber in This Decision

This is not a decision any patient should make based on an article alone. What an article can do is give you the information and the framework. What it cannot do is review your clinical history, your previous treatment experience, your current medications, or your BMI and comorbidities. That is what a prescriber consultation is for.

At Pharmacy Planet, every weight loss consultation is carried out as part of a structured online consultation, reviewed by qualified UK prescribers operating under GPhC standards. Nothing is dispensed without that step. If you are ready to have that conversation, you can start a consultation here.

What About Mounjaro as an Alternative?

Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors. Wegovy targets GLP-1 only. NICE approved tirzepatide for weight management in March 2024 via Technology Appraisal TA1026. The SURMOUNT clinical trial programme showed average weight reductions exceeding 20% of body weight at the highest doses in some patient groups, which is notably higher than what the STEP trials showed for semaglutide.

If you tried the semaglutide injection and did not achieve the results you needed, the dual mechanism of tirzepatide is a clinically rational next step to explore with a prescriber. You can read a detailed comparison in our article on Wegovy vs Mounjaro.

Making an Informed Decision: Questions Worth Discussing With a Prescriber

• What specifically caused you to stop or feel dissatisfied with the injections? Side effects, insufficient results, practical difficulties, and injection anxiety all lead to different clinical conversations.
• Has your BMI or any health condition changed since your previous treatment? This matters for eligibility and for the choice of treatment.
• Are you currently taking any other medication that might interact with oral semaglutide?
• What dose and duration would a prescriber recommend given your specific history?
• Are there other licensed treatments in this class that may be more appropriate for you individually? Mounjaro in particular is worth asking about if semaglutide alone did not deliver sufficient results.

A Realistic Summary

The Wegovy tablet and the Wegovy injection contain the same active ingredient, but they are not the same clinical experience. They absorb differently, they are dosed differently, and they suit different patients for different reasons. The tablet is not automatically a better option just because it is newer or because you struggled with the injection.

The fact that the injections did not work as hoped is information, not a dead end. It tells us something about your specific situation that a good prescriber can work with. For some people, the tablet will be a genuinely useful alternative. For others, a different treatment altogether may be the answer. But that conversation has to happen properly, with someone who can review your full picture.

You can view the full range of weight loss treatments available through Pharmacy Planet or review the Wegovy page for consultation and treatment details.

Frequently Asked Questions

Is there a Wegovy tablet available in the UK?

Yes. As of 11 June 2026, the MHRA approved the semaglutide (Wegovy) tablet as the first GLP-1 receptor agonist tablet licensed for weight loss and weight management in the UK. It can be prescribed alongside a reduced-calorie diet and increased physical activity to adults with a BMI of 30 or above, or those with obesity-related health conditions. The tablet follows a stepped dosing schedule, beginning at 1.5mg once daily and increasing through 4mg and 9mg to a maintenance dose of 25mg. As with all prescription weight loss treatments, it must only be accessed following a clinical consultation with a qualified prescriber.

Why did Wegovy injections stop working for me?

Weight loss with GLP-1 receptor agonists can plateau for several reasons including physiological adaptation, changes in lifestyle adherence, or individual variation in how your body responds to the medication. "Stopped working" is worth unpacking properly with a prescriber rather than assuming the treatment has simply run its course. There may be more to explore.

Can I switch from Wegovy injections to oral semaglutide on my own?

No. Any change in prescription medication needs to go through a qualified prescriber. Oral and injectable semaglutide are different products with different doses, different absorption profiles, and different licensing indications. Switching without clinical oversight is not appropriate and could mean you end up on a dose or formulation that is not right for your circumstances.

Is oral semaglutide as effective as the injection for weight loss?

Following the MHRA approval of the Wegovy tablet in June 2026, oral semaglutide at 25mg is now licensed for weight management in the UK, with clinical trial data showing results broadly comparable to the injectable form. That said, individual response always varies, and the right formulation depends very much on the individual patient. A prescriber is best placed to advise on which option makes sense for you specifically.

What is Mounjaro, and is it better than Wegovy?

Mounjaro contains tirzepatide, which works on both GLP-1 and GIP receptors, whereas Wegovy works on GLP-1 only. NICE approved Mounjaro for weight management in March 2024. Some clinical trials have shown greater average weight loss with tirzepatide compared to semaglutide, and for patients who have not achieved sufficient results with semaglutide-based treatments, it is absolutely worth discussing with a prescriber. Whether it is the right choice for you depends on your individual clinical history.

How do I know which weight loss treatment is right for me?

This is exactly the kind of question that needs a proper consultation rather than an article. A GPhC-registered prescriber will look at your BMI, your health conditions, your medication history, and your previous treatment experience before making a recommendation. No reputable provider should supply prescription weight loss treatment without going through that process, and at Pharmacy Planet we take that seriously.